View in EDS

Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.

Saved in:
Bibliographic Details
Title: Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
Authors: Jain H; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Karulkar A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Kalra D; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Ravikumar S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Shah S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Firfiray A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Pendhari J; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Jaiswal AK; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Khan A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Sundharam M; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Vaibhaw A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Saroha A; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Rajyopadhye S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Basu M; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Asija S; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Chowdhury A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Beher R; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Banik A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Dwivedi A; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India., Purwar S; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India., Narula G; Department of Pediatric Oncology, Tata Memorial Centre, Mumbai, India., Banavali S; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Highfill SL; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA., Stroncek D; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA., Fry T; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA; Hematology, Oncology and Bone Marrow Transplantation Section, Department of Pediatrics, University of Colorado Hospital, Children's Hospital Colorado, CO, USA., Melinkeri S; Deenanath Mangeshkar Hospital, Pune, Maharashtra, India., Wilson L; SMBT Hospital, Nashik, India., Agarwal N; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India., Aribandi A; American Oncology Institute, Hyderabad, India., Boyella PK; Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India., Shah NN; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sengar M; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India., Purwar R; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India. Electronic address: rahul.purwar@immunoact.com.
Corporate Authors: CAR-T clinical trial group
Source: The Lancet. Haematology [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e282-e293. Date of Electronic Publication: 2025 Mar 13.
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40090352
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jain+H%22">Jain H</searchLink>; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Karulkar+A%22">Karulkar A</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Kalra+D%22">Kalra D</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Ravikumar+S%22">Ravikumar S</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Shah+S%22">Shah S</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Firfiray+A%22">Firfiray A</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Pendhari+J%22">Pendhari J</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Jaiswal+AK%22">Jaiswal AK</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Khan+A%22">Khan A</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Sundharam+M%22">Sundharam M</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Vaibhaw+A%22">Vaibhaw A</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Saroha+A%22">Saroha A</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Rajyopadhye+S%22">Rajyopadhye S</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Basu+M%22">Basu M</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Asija+S%22">Asija S</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Chowdhury+A%22">Chowdhury A</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Beher+R%22">Beher R</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Banik+A%22">Banik A</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Dwivedi+A%22">Dwivedi A</searchLink>; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Purwar+S%22">Purwar S</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Narula+G%22">Narula G</searchLink>; Department of Pediatric Oncology, Tata Memorial Centre, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Banavali+S%22">Banavali S</searchLink>; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Jain+N%22">Jain N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Highfill+SL%22">Highfill SL</searchLink>; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Stroncek+D%22">Stroncek D</searchLink>; Transfusion Medicine Department, National Institute of Health Clinical Center, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Fry+T%22">Fry T</searchLink>; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA; Hematology, Oncology and Bone Marrow Transplantation Section, Department of Pediatrics, University of Colorado Hospital, Children's Hospital Colorado, CO, USA.<br /><searchLink fieldCode="AU" term="%22Melinkeri+S%22">Melinkeri S</searchLink>; Deenanath Mangeshkar Hospital, Pune, Maharashtra, India.<br /><searchLink fieldCode="AU" term="%22Wilson+L%22">Wilson L</searchLink>; SMBT Hospital, Nashik, India.<br /><searchLink fieldCode="AU" term="%22Agarwal+N%22">Agarwal N</searchLink>; Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.<br /><searchLink fieldCode="AU" term="%22Aribandi+A%22">Aribandi A</searchLink>; American Oncology Institute, Hyderabad, India.<br /><searchLink fieldCode="AU" term="%22Boyella+PK%22">Boyella PK</searchLink>; Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India.<br /><searchLink fieldCode="AU" term="%22Shah+NN%22">Shah NN</searchLink>; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.<br /><searchLink fieldCode="AU" term="%22Neelapu+SS%22">Neelapu SS</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Sengar+M%22">Sengar M</searchLink>; Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Purwar+R%22">Purwar R</searchLink>; Immunoadoptive Cell Therapy (ImmunoACT), Mumbai, India; Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay (IIT Bombay), Mumbai, India. Electronic address: rahul.purwar@immunoact.com.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22CAR-T+clinical+trial+group%22">CAR-T clinical trial group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2025 Apr; Vol. 12 (4), pp. e282-e293. <i>Date of Electronic Publication: </i>2025 Mar 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40090352
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2352-3026(24)00377-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e282
    Titles:
      – TitleFull: Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jain H
      – PersonEntity:
          Name:
            NameFull: Karulkar A
      – PersonEntity:
          Name:
            NameFull: Kalra D
      – PersonEntity:
          Name:
            NameFull: Ravikumar S
      – PersonEntity:
          Name:
            NameFull: Shah S
      – PersonEntity:
          Name:
            NameFull: Firfiray A
      – PersonEntity:
          Name:
            NameFull: Pendhari J
      – PersonEntity:
          Name:
            NameFull: Jaiswal AK
      – PersonEntity:
          Name:
            NameFull: Khan A
      – PersonEntity:
          Name:
            NameFull: Sundharam M
      – PersonEntity:
          Name:
            NameFull: Vaibhaw A
      – PersonEntity:
          Name:
            NameFull: Saroha A
      – PersonEntity:
          Name:
            NameFull: Rajyopadhye S
      – PersonEntity:
          Name:
            NameFull: Basu M
      – PersonEntity:
          Name:
            NameFull: Asija S
      – PersonEntity:
          Name:
            NameFull: Chowdhury A
      – PersonEntity:
          Name:
            NameFull: Beher R
      – PersonEntity:
          Name:
            NameFull: Banik A
      – PersonEntity:
          Name:
            NameFull: Dwivedi A
      – PersonEntity:
          Name:
            NameFull: Purwar S
      – PersonEntity:
          Name:
            NameFull: Narula G
      – PersonEntity:
          Name:
            NameFull: Banavali S
      – PersonEntity:
          Name:
            NameFull: Jain N
      – PersonEntity:
          Name:
            NameFull: Highfill SL
      – PersonEntity:
          Name:
            NameFull: Stroncek D
      – PersonEntity:
          Name:
            NameFull: Fry T
      – PersonEntity:
          Name:
            NameFull: Melinkeri S
      – PersonEntity:
          Name:
            NameFull: Wilson L
      – PersonEntity:
          Name:
            NameFull: Agarwal N
      – PersonEntity:
          Name:
            NameFull: Aribandi A
      – PersonEntity:
          Name:
            NameFull: Boyella PK
      – PersonEntity:
          Name:
            NameFull: Shah NN
      – PersonEntity:
          Name:
            NameFull: Neelapu SS
      – PersonEntity:
          Name:
            NameFull: Sengar M
      – PersonEntity:
          Name:
            NameFull: Purwar R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2025 Apr
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3026
          Numbering:
            – Type: volume
              Value: 12
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: The Lancet. Haematology
              Type: main
ResultId 1